Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062270 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00062270 is a Phase 1 study that has completed, run by University of Alabama at Birmingham.
The verdict
NCT00062270, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the tumor. Combining chemotherapy and radiation therapy with gefitinib before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: Phase I/II trial to compare the effectiveness of neoadjuvant chemoradiotherapy with or without gefitinib in treating patients who are undergoing surgery for stage III non-small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG docetaxel
- PROCEDURE conventional surgery
- DRUG gemcitabine hydrochloride
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-05 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062270
The ClinicalTrials.gov registry entry for NCT00062270 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00062270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062270 about?
NCT00062270 is a clinical study titled "Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of the ...
What is the current status of trial NCT00062270?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-05. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00062270?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), conventional surgery (PROCEDURE), gemcitabine hydrochloride (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00062270?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.